Seelos Therapeutics Stock (NASDAQ:SEEL)
Previous Close
$0.23
52W Range
$0.20 - $254.40
50D Avg
$0.42
200D Avg
$5.65
Market Cap
$1.59M
Avg Vol (3M)
$1.98M
Beta
1.86
Div Yield
-
SEEL Company Profile
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
SEEL Performance
Peer Comparison
Ticker | Company |
---|---|
SLNO | Soleno Therapeutics, Inc. |
ATAI | Atai Life Sciences N.V. |
PULM | Pulmatrix, Inc. |
HSTO | Histogen Inc. |
EWTX | Edgewise Therapeutics, Inc. |
GHRS | GH Research PLC |
MNMD | Mind Medicine (MindMed) Inc. |
CAPR | Capricor Therapeutics, Inc. |
DFFN | CervoMed Inc. |
AKTX | Akari Therapeutics, Plc |
ITOS | iTeos Therapeutics, Inc. |
TPST | Tempest Therapeutics, Inc. |
ENTX | Entera Bio Ltd. |
MOLN | Molecular Partners AG |
OPT | Opthea Limited |
ELYM | Eliem Therapeutics, Inc. |